Serum lipidome screening in patients with stage I non-small cell lung cancer
Tóm tắt
The ability of early lung cancer diagnosis is an unmet need in clinical practice. Lung cancer metabolomic analyses conducted so far have demonstrated several abnormalities in cancer lipid profile providing a rationale for further study of blood lipidome of the patients. In the present research, we performed a targeted lipidome screening to select molecules that show promise for early lung cancer detection. The study was conducted on serum samples collected from newly diagnosed, stage I non-small cell lung cancer (NSCLC) patients and non-cancer controls. A high-throughput mass spectrometry-based platform with confirmed interlaboratory reproducibility was used. The analyzed profile consisted of acylcarnitines, sphingomyelins, phosphatidylcholines and lysophosphatidylcholines. Among the assayed lipid species, the significant differences between NSCLC and non-cancer subjects were observed in the group of phosphatidylcholines (PC) and lysophosphatidylcholines (lysoPC), especially in the levels of lysoPC a C26:0; lysoPC a C26:1; PC aa C42:4; and PC aa C34:4. The metabolites mentioned above were used to create a multivariate classification model, which reliability was proved by permutation tests as well as external validation. Our study indicated choline-containing phospholipids as potential lung cancer markers. Further investigations of phospholipidome are crucial to better describe the shifts in metabolite composition occurring in lung cancer patients.
Tài liệu tham khảo
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Puchades-Carrasco L, Jantus-Lewintre E, Pérez-Rambla C, Camps C, Pineda-Lucena A. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget. 2016;7:12904–16.
Chen Y, Ma Z, Zhong J, et al. Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer. Sci Rep. 2018;8:7137.
Li Y, Song X, Zhao X, Zou L, Xu G. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr, B: Anal Technol Biomed Life Sci. 2014;966:147–53.
Klupczynska A, Dereziński P, Garrett TJ, et al. Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics. J Cancer Res Clin Oncol. 2017;143:649–59.
Dong J, Cai X, Zhao L, et al. Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics. 2010;6:478–88.
Guo Y, Wang X, Qiu L, et al. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clin Chim Acta. 2012;414:135–41.
Ros-Mazurczyk M, Jelonek K, Marczyk M, et al. Serum lipid profile discriminates patients with early lung cancer from healthy controls. Lung Cancer. 2017;112:69–74.
Liu J, Mazzone PJ, Cata JP, et al. Serum free fatty acid biomarkers of lung cancer. Chest. 2014;146:670–9.
Yu Z, Chen H, Ai J, et al. Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer. Oncotarget. 2017;8:107899–906.
Qiu Y, Zhou B, Su M, et al. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci. 2013;14:8047–61.
Bathe OF, Farshidfar F. From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer. Genes (Basel). 2014;5:536–60.
Giskeødegård GF, Hansen AF, Bertilsson H, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. Br J Cancer. 2015;113:1712–9.
Di Gangi IM, Mazza T, Fontana A, et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7:5815–29.
Plewa S, Horała A, Dereziński P, Nowak-Markwitz E, Matysiak J, Kokot ZJ. Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers. Life Sci. 2019;222:235–44.
Panneerselvam J, Xie G, Che R, et al. Distinct metabolic signature of human bladder cancer cells carrying an impaired fanconi anemia tumor-suppressor signaling pathway. J Proteome Res. 2016;15:1333–41.
Schmerler D, Neugebauer S, Ludewig K, Bremer-Streck S, Brunkhorst FM, Kiehntopf M. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J Lipid Res. 2012;53:1369–75.
US Department of Health and Humans Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation. 2001. https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf. Accessed 13 Dec 2018.
Chong J, Soufan O, Li C, et al. MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018;46:W486–94.
Wang-Sattler R, Yu Y, Mittelstrass K, et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans—first results from the KORA study. PLoS ONE. 2008;3:e3863.
Xu T, Holzapfel C, Dong X, et al. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med. 2013;11:60.
Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279:2610–23.
Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2016;36:e00281.
Makrecka-Kuka M, Sevostjanovs E, Vilks K, et al. Plasma acylcarnitine concentrations reflect the acylcarnitine profile in cardiac tissues. Sci Rep. 2017;7:17528.
Gibellini F, Smith TK. The Kennedy pathway-de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life. 2010;62:414–28.
Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11:835–48.
Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwalla ZM. Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn. 2015;15:735–47.
Janardhan S, Srivani P, Sastry GN. Choline kinase: an important target for cancer. Curr Med Chem. 2006;13:1169–86.
Trousil S, Lee P, Pinato DJ, Ellis JK, Dina R, Aboagye EO, et al. Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway. Cancer Res. 2014;74:6867–77.
Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010;70:2126–35.
Iorio E, Caramujo MJ, Cecchetti S, Spadaro F, Carpinelli G, Canese R, et al. Key players in choline metabolic reprograming in triple-negative breast cancer. Front Oncol. 2016;6:205.
Yu L, Li K, Zhang X. Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review. Oncotarget. 2017;8:115774–86.
Marien E, Meister M, Muley T, et al. Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles. Int J Cancer. 2015;137:1539–48.
Ridgway ND. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit Rev Biochem Mol Biol. 2013;48:20–38.
Quehenberger O, Armando AM, Brown AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010;51:3299–305.
Cheng M, Bhujwalla ZM, Glunde K. Targeting phospholipid metabolism in cancer. Front Oncol. 2016;6:266.
Lv J, Gao D, Zhang Y, Wu D, Shen L, Wang X. Heterogeneity of lipidomic profiles among lung cancer subtypes of patients. J Cell Mol Med. 2018;22:5155–9.
Jelonek K, Ros M, Pietrowska M, Widlak P. Cancer biomarkers and mass spectrometry-based analyses of phospholipids in body fluids. Clin Lipidol. 2013;8:137–50.
Süllentrop F, Moka D, Neubauer S, Haupt G, Engelmann U, Hahn J, et al. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 2002;15:60–8.
Law SH, Chan ML, Marathe GK, Parveen F, Chen CH, Ke LY. An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci. 2019;20:1149.
Moessinger C, Klizaite K, Steinhagen A, Philippou-Massier J, Shevchenko A, Hoch M, et al. Two different pathways of phosphatidylcholine synthesis, the Kennedy Pathway and the Lands Cycle, differentially regulate cellular triacylglycerol storage. BMC Cell Biol. 2014;15:43.
Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem. 2007;14:3209–20.
Sato A, Ebina K. Endothelins specifically recognize lysophosphatidylcholine micelles. J Pept Sci. 2013;19:355–61.
Dong J, et al. Lysophosphatidylcholine biomarkers of lung cancer detected by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Chem Resour Chinese Univ. 2011;27:750–5.
Marien E, Meister M, Muley T, del Pulgar TG, Derua R, Spraggins JM, et al. Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget. 2016;7:12582–97.
Siskos AP, Jain P, Römisch-Margl W, et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal Chem. 2017;89:656–65.
Murphy RC. Challenges in mass spectrometry-based lipidomics of neutral lipids. TrAC - Trends Anal Chem. 2018;107:91–8.